Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 33-52 , March 2003

The menopausal transition: characteristics and management

  • Nanette Santoro, MD (Professor and Director)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1-718-430-3152; Fax: +1-718-430-8586.

Received 1 July 2002 ,Accepted 1 September 2002.

References 

  1. Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. Journal of Clinical Endocrinology and Metabolism. 1987;65:1231–1236
  2. Piette C, deMouzon J, Bachelot A, Spira A. In-vitro fertilization: influence of women's age on pregnancy rates. Human Reproduction. 1990;5:56–59
  3. Ahmed-Ebbiary NA, Lenton EA, Cooke ID. Hypothalamic-pituitary ageing: progressive increase in FSH and LH concentrations throughout the reproductive life in regularly menstruating women. Clinical Endocrinology. 1994;41:199–206
  4. Roberts VJ, Barth S, el-Roiey A, Yen SSC. Expression of inhibin/activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle. Journal of Clinical Endocrinology and Metabolism. 1993;77:1402–1410
  5. Burger HG, Dudley EC, Hopper JL, et al.  Prospectively measured levels of serum follicle-stimulating hormone, oestradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. Journal of Clinical Endocrinology and Metabolism. 1999;84:4025–4030
  6. Klein NA, Battaglia DE, Miller PB, et al.  Ovarian follicular development and the follicular fluid hormones and growth factors in normal women of advanced reproductive age. Journal of Clinical Endocrinology and Metabolism. 1996;81:1946–1951
  7. Burger HG, Cahir N, Robertson DM, et al.  Serum inhibins A and B fall differentially as FSH rises in perimenopausal women. Clinical Endocrinology. 1998;48:809–813
  8. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. Journal of Clinical Endocrinology and Metabolism. 1996;81:1495–1501
  9. Soules MR, Sherman S, Parrott E, et al.  Executive summary: stages of reproductive aging workshop (STRAW). Fertility and Sterility. 2001;76:874–878
  10. McKinlay SM, Brambilla D, Posner J. The normal menopause transition. Maturitas. 1992;14:103–115
  11. Mitchell ES, Woods NF. Symptom experiences of midlife women: observations from the Seattle midlife women's health study. Maturitas. 1996;25:1–10
  12. Dennerstein L, Dudley EC, Hopper JL, et al.  A prospective population-based study of menopausal symptoms. Obstetrics and Gynecology. 2000;96:351–358
  13. Guthrie JR, Dennerstein L, Hopper JL, Burger HG. Hot flushes, menstrual status and hormone levels in a population-based sample of midlife women. Obstetrics and Gynecology. 1996;88:437–442
  14. Overlie I, Moen MH, Holte A, Finset A. Androgens and estrogens in relation to hot flushes during the menopausal transition. Maturitas. 2002;41:69–77
  15. Hollander LE, Freeman EW, Sammel MD, et al.  Sleep quality, oestradiol levels, and behavioral factors in late reproductive age women. Obstetrics and Gynecology. 2001;98:391–397
  16. Wang M, Seippel L, Purdy H, Backstrom T. Relationship between symptom severity and steroid variation in women with pre-menstrual syndrome; study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one. Journal of Clinical Endocrinology and Metabolism. 1996;81:1076–1082
  17. Freeman EW, Rickels K, Yonders KA, et al.  Venlafaxine in the treatment of pre-menstrual dysphoric disorder. Obstetrics and Gynecology. 2001;98:737–744
  18. Stearns V, Isaacs C, Rowland J, et al.  A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Annals of Oncology. 2000;11:17–22
  19. Casper RF, Dodin S, Reid RL, et al.  The effect of 20μg ethinyl oestradiol/1mg norethindrone acetate (Minestrin), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women. Menopause. 1997;4:139–147
  20. Audet MC, Moreau M, Koltun WD, et al.  Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. Journal of the American Medical Association. 2001;285:2347–2354
  21. Greendale GA, Reboussin BA, Hogan P, et al.  Symptom relief and side effects of post-menopausal hormones: results from the post-menopausal estrogen/progestin interventions trial. Obstetrics and Gynecology. 1998;92:982–988
  22. Utian WH, Shoupe D, Bachmann G, et al.  Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertility and Sterility. 2001;75:1065–1079
  23. Pickar JH, Yeh I-T, Wheeler JE, et al.  Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertility and Sterility. 2001;76:25–31
  24. Archer DF, Dorin M, Lewis V, et al.  Effects of lower doses of conjugated equine estrogens and medroxyprogestorone acetate on endometrial bleeding. Fertility and Sterility. 2001;75:1080–1087
  25. Lobo RA, Bush T, Carr BR, et al.  Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertility and Sterility. 2001;76:13–24
  26. Notelovitz M, Cassel D, Hille D, et al.  Efficacy of continuous sequential transdermal oestradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. American Journal of Obstetrics and Gynecology. 2000;182:7–12
  27. von Holst T, Salbach B. Efficacy of a new 7-day transdermal sequential estadiol/levonorgestrel patch in women. Maturitas. 2002;41:231–242
  28. Loprinzi CL, Kugler JW, Sloan JA, et al.  Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet. 2000;356:2059–2063
  29. Loprinzi CL, Sloan JA, Perez EA, et al.  Phase III evaluation of fluoxetine for treatment of hot flashes. Journal of Clinical Oncology. 2002;20:1578–1583
  30. Goldberg RM, Loprinzi CL, O'Fallon JR, et al.  Transdermal clonidine for ameliorating Tamoxifen-induced hot flashes. Journal of Clinical Oncology. 1994;12:155–158
  31. Pandya KJ, Raubertas RF, Flynn PJ, et al.  Oral clonidine in post-menopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program Study. Annals of Internal Medicine. 2000;132:788–793
  32. Edington RF, Chagnon JP. Clonidine (Dixarit) for menopausal flushing. Canadian Medical Association Journal. 1980;123:23–26
  33. Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. American Journal of Obstetrics and Gynecology. 1987;156:561–565
  34. Loprinzi CL, Michalak JC, Quella SK, et al.  Megestrol acetate for the prevention of hot flashes. New England Journal of Medicine. 1994;331:347–352
  35. Paterson ME. A randomized double-blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles. British Journal of Obstetrics and Gynaecology. 1982;89:464–472
  36. Aslaksen K, Frankendal B. Effect of oral medroxyprogesterone acetate on menopausal symptoms in patients with endometrial carcinoma. Acta Obstetricia et Gynecologica Scandinavica. 1982;61:423–428
  37. Schiff I, Tulchinsky D, Cramer D, Ryan KJ. Oral medroxyprogesterone in the treatment of post-menopausal symptoms. Journal of the American Medical Association. 1980;244:1443–1445
  38. Lobo RA, McCormick W, Singer F, Roy S. DMPA compared with conjugated estrogens for the treatment of post-menopausal women. Obstetrics and Gynecology. 1984;63:1–5
  39. Hammar M, Christau S, Nathorst-Boos J, et al.  A double-blind, randomized trial comparing the effects of tibolone and continuous combined hormone replacement therapy in post-menopausal women with menopausal symptoms. British Journal of Obstetrics and Gynaecology. 1998;105:904–911
  40. Kicovic PM, Cortes-Prieto J, Luisi M, et al.  Placebo-controlled cross-over study of effects of Org OD14 in menopausal women. Reproduccion. 1982;6:81–91
  41. Vercellini P, Sacerdote P, Trespidi L, et al.  Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: a controlled study. Fertility and Sterility. 1994;62:938–942
  42. Stadberg E, Mattsson LA, Milsom I. Factors associated with climacteric symptoms and the use of hormone replacement therapy. Acta Obstetricia et Gynecologica Scandinavica. 2000;79:286–292
  43. Freeman EW, Sammel MD, Grisso JA, et al.  Hot flashes in the late reproductive years: risk factors for African American and Caucasian women. Journal of Women's Health and Gender-Based Medicine. 2001;10:67–76
  44. Albertazzi P, Pansini F, Bonaccorsi G, et al.  The effect of dietary soy supplementation on hot flushes. Obstetrics and Gynecology. 1998;91:6–11
  45. Quella SK, Lopinzi CL, Barton DL, et al.  Evaluation of soy phytestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. Journal of Clinical Oncology. 2000;18:1068–1074
  46. Van Patten CL, Olivotto IA, Chambers GK, et al.  Effect of soy phytoestrogens on hot flashes in post-menopausal women with breast cancer: a randomized, controlled clinical trial. Journal of Clinical Oncology. 2002;20:1449–1455
  47. Lebherz TB, French L. Nonhormonal treatment of the menopausal syndrome. A double-blind evaluation of an autonomic system stabilizer. Obstetrics and Gynecology. 1969;33:795–799
  48. Barton DL, Loprinzi CL, Quella SK, et al.  Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. Journal of Clinical Oncology. 1998;16:495–500
  49. Foster S. Black cohash (Cimicifuga racemosa): a literature review. Herbalgram. 1999;45:35–49
  50. Jacobson JS, Troxel AB, Evans J, et al.  Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. Journal of Clinical Oncology. 2001;19:2739–2745
  51. Hirata JD, Swiersz LM, Zell B, et al.  Does dong quai have estrogenic effects in post-menopausal women? A double-blind, placebo-controlled trial. Fertility and Sterility. 1997;68:981–986
  52. Chenoy R, Hussain S, Tayob Y, et al.  Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. British Medical Journal. 1994;308:501–503
  53. Coope J, Williams S, Patterson JS. A study of the effectiveness of propranolol in menopausal hot flushes. British Journal of Obstetrics and Gynaecology. 1978;85:472–475
  54. Cardozo L, Bachmann G, McClish D, et al.  Meta-analysis of estrogen therapy in the management of urogenital atrophy in post-menopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstetrics and Gynecology. 1998;92:722–727
  55. Casper F, Petri E. Local treatment of urogenital atrophy with an oestradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter sudy. Vaginal Ring Study Group. International Urogynecology Journal and Pelvic Floor Dysfunction. 1999;10:171–176
  56. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an oestradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in post-menopausal women. American Journal of Obstetrics and Gynecology. 1999;180:1072–1079
  57. Mattsson L-A. Clinical experience with continuous combined transdermal hormone replacement therapy. Journal für Menopause. 1999;6:25–29
  58. Santen RJ, Pinkerton JV, Conaway M, et al.  Treatment of urogenital atrophy with low-dose oestradiol: preliminary results. Menopause. 2002;9:179–187
  59. Dennerstein L, Randolph J, Taffe J, et al.  Hormones, mood, sexuality, and the menopausal transition. Fertility and Sterility. 2002;77(supplement 4):S42–S48
  60. Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during the midlife years due to ageing or menopause?. Fertility and Sterility. 2001;76:456–460
  61. Dennerstein L, Lehert P, Burger H, Dudley E. Mood and the menopausal transition. Journal of Nervous and Mental Disease. 1999;187:685–691
  62. Dennerstein L, Dudley E, Guthrie J, Barrett-Connor E. Life satisfaction, symptoms, and the menopausal transition. Medscape Womens Health. 2000;5:E4
  63. Banger M. Affective syndrome during perimenopause. Maturitas. 2002;41(supplement 1):S13–S18
  64. Dennerstein L, Lehert P, Burger H, Dudley E. Factors affecting sexual functioning of women in the mid-life years. Climacteric. 1999;2:254–262
  65. Dennerstein L, Burrows GD, Wood C, Hyman G. Hormones and sexuality: effect of estrogen and progestogen. Obstetrics and Gynecology. 1980;56:316–322
  66. Brambilla DJ, McKinlay SM, Johannes CB. Defining the perimenopause for application in epidemiologic investigations. American Journal of Epidemiology. 1994;140:1091–1095
  67. Dudley EC, Hopper JL, Taffe J, et al.  Using longitudinal data to define the perimenopause by menstrual cycle characteristics. Climacteric. 1998;i:18–25
  68. Mitchell ES, Woods NF, Marella A. Three stages of the menopausal transition from the Seattle Midlife Women's Health Study: toward a more precise definition. Menopause. 2000;7:334–349
  69. Wilcox LS, Koonin LM, Pokras R, et al.  Hysterectomy in the United States 1988–1990. Obstetrics and Gynecology. 1994;83:549–555
  70. Cano A, Gimeno F, Fuente T, et al.  The positive feedback of oestradiol on gonadotropin secretion in women with perimenopausal dysfunctional uterine bleeding. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 1986;22:353–358
  71. Fraser IS, Baird D. Blood production and ovarian secretion rates of oestradiol-17β and estrone in women with dysfunctional uterine bleeding. Journal of Clinical Endocrinology and Metabolism. 1974;39:564–570
  72. Legan SJ, Callahan WH. Suppression of tonic luteinizing hormone secretion and norepinephrine release near the GnRH neurons by oestradiol in ovariectomized rats. Neuroendocrinology. 1999;70:237–245
  73. LaPolt PS, Matt DW, Lu JK. Progesterone implants delay age-related declines in regular estrous cyclicity in the ovarian follicular reserve in Long–Evans rats. Biology of Reproduction. 1998;59:197–201
  74. Seltzer VL, Benjamin F, Deutsch S. Perimenopausal bleeding patterns and pathologic findings. Journal of the American Medical Womens Association. 1990;45:132–134
  75. Bhattacharya S, Cameron IM, Parkin DE, et al.  A pragmatic randomized comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology. 1997;104:601–607
  76. Aberdeen Endometrial Ablation Trials Group . A randomized trial of endometrial ablation versus hysterectomy for the treatment of dysfunctional uterine bleeding: outcome at four years. British Journal of Obstetrics and Gynaecology. 1999;106:360–366
  77. Amso NN, Stabinsky SA, McFaul P, et al.  Uterine thermal balloon therapy for the treatment of menorrhagia: the first 300 patients from a multicentre study. International Collaborative Uterine Thermal Balloon Working Group. British Journal of Obstetrics and Gynaecology. 1998;105:517–523
  78. Lethaby A, Irvine G & Cameron I. Cyclical progestogens for heavy menstrual bleeding (Cochrane Review). The Cochrane Library. Issue 2, Oxford: Update Software; 2002.
  79. Henshaw SK. Unintended pregnancy in the United States. Family Planning Perspectives. 1998;30:24–29 see also p. 46
  80. Gebbie AE, Glasier A, Sweeting V. Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. Contraception. 1995;52:221–222
  81. Davis A, Godwin A, Lippman J, et al.  Triphasic norgestimate-ethinyl oestradiol for treating dysfunctional uterine bleeding. Obstetrics and Gynecology. 2000;96:913–920
  82. Sulak P, Lippman J, Siu C, et al.  Clinical comparison of triphasic norgestimate/35μg ethinyl oestradiol and monophasic norethindrone acetate/20μg ethinyl oestradiol. Contraception. 1999;59:161–166
  83. Hampton RM, Short M, Bieber E, et al.  Comparison of a novel norgestimate/ethinyl oestradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception. 2001;63:289–295
  84. Jick H, Kaye JA, Vasilakis-Scaramozza C, et al.  Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. British Medical Journal. 2000;321:1190–1195
  85. Tanis BC, Van Der Bosch MAAJ, Kemmeren JM, et al.  Oral contraceptives and the risk of myocardial infarction. New England Journal of Medicine. 2001;345:1787–1793
  86. Marchbanks PA, McDonald JA, Wilson HG, et al.  Oral contraceptives and the risk of breast cancer. New England Journal of Medicine. 2002;346:2025–2032
  87. Milsom I, Sundell G, Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception. 1990;42:497–506
  88. Ness RB, Grisso JA, Klapper J, et al.  Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. American Journal of Epidemiology. 2000;152:233–241
  89. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development . The reduction in risk of ovarian cancer associated with oral-contraceptive use. New England Journal of Medicine. 1987;316:650–655
  90. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives; a practitioner's guide to meta-analysis. Human Reproduction. 1997;12:1851–1863
  91. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development . Combination oral contraceptive use and the risk of endometrial cancer. Journal of the American Medical Association. 1987;257:796–800
  92. Sulak PJ, Scow RD, Preece C, et al.  Hormone withdrawal symptoms in oral contraceptive users. Obstetrics and Gynecology. 2000;95:261–266
  93. den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception. 1999;59:357–362
  94. World Health Organization. Cardiovascular disease and steroid hormone contraception. Report of a WHO scientific group. WHO Technical Bulletin series 877. Geneva: WHO, 1998.
  95. ACOG Practice Bulletin . The use of hormonal contraception in women with coexisting medical conditions. No. 18, July 2000. International Journal of Gynaecology & Obstetrics. 2001;75:93–106
  96. McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. Annals of Internal Medicine. 1985;103:350–356
  97. Scarselli G, Tantini C, Colafranceschi M, et al.  Levonorgestrel-nova-T and precancerous lesions of the endometrium. European Journal of Gynaecological Oncology. 1988;9:284–286
  98. Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Australian and New Zealand Journal of Obstetrics and Gynaecology. 1990;30:353–356
  99. Andersson K, Mattsson LA, Rybo G, Stadberg E. Intrauterine release of levonorgestrel-a new way of adding progestogen in hormone replacement therapy. Obstetrics and Gynecology. 1992;79:963–967
  100. Said S, Omar K, Koetsawang S, et al.  A multicentered phase III comparative clinical trial of depot medroxyprogesterone acetate given three-monthly at doses of 100mg or 150mg: II. The comparison of bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1987;35:591–610
  101. Berenson AB, Radecki CM, Grady JJ. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstetrics and Gynecology. 2001;98:576–582
  102. Seifer-Klauss V, Mueller JE, Luppa P, et al.  Bone metabolism during the perimenopausal transition: a prospective study. Maturitas. 2002;41:23–33
  103. Ebeling PR, Atley LM, Guthrie JR, et al.  Bone turnover markers and bone density across the menopausal transition. Journal of Clinical Endocrinology and Metabolism. 1996;81:3366–3371
  104. Gambacciani M, Spinetti A, Cappagli B, et al.  Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: effects on bone mineral density and metabolism. Maturitas. 1994;19:125–131
  105. Pasco JA, Kotowicz MA, Henry MJ, et al.  Oral contraceptives and bone mineral density: a population-based study. American Journal of Obstetrics and Gynecology. 2000;182:265–269
  106. Michaelsson K, Baron JA, Farahmand BY, et al.  Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet. 1999;353:1481–1484
  107. Alekel DL, St Germain A, Peteson CT, et al.  Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. American Journal of Clinical Nutrition. 2000;72:844–852
  108. Mei J, Yeung SS, Kung AW. High dietary phytoestrogen intake is associated with higher bone mineral density in post-menopausal but not pre-menopausal women. Journal of Clinical Endocrinology and Metabolism. 2001;86:5217–5221
  109. Greendale GA, FitzGerald G, Huang M-H, et al.  Dietary soy isoflavones and bone mineral density; results from the Study of Women's Health Across the Nation. American Journal of Epidemiology. 2002;155:746–754
  110. Blumel JE, Castelo-Branco C, Rocangliolo ME, et al.  Changes in body mass index around menopause; a population study of Chilean woman. Menopause. 2001;8:239–244
  111. Crawford SL, Casey VA, Avis NE, McKinlay SM. A longitudinal study of weight and the menopause transition: results from the Massachusetts Women's Health Study. Menopause. 2000;7:96–104
  112. Guthrie JR, Dennerstein L, Dudley EC. Weight gain and the menopause: a 5-year prospective study. Climacteric. 1999;ii:205–211
  113. Matthews KA, Abrams B, Crawford S, et al.  Body mass index in mid-life women: relative influence of menopause, hormone use, and ethnicity. International Journal of Obesity. 2001;25:863–873
  114. Luoto R, Sharrett AR, Schreiner P, et al.  Blood pressure and menopausal transition: the Atherosclerosis Risk in Communities study (1987–95). Journal of Hypertension. 2000;18:27–33
  115. Do KA, Green A, Guthrie JR, et al.  Longitudinal study of risk factors for coronary heart disease across the menopausal transition. American Journal of Epidemiology. 2000;151:584–593
  116. Hall G, Collins A, Csemiczky G, Landgren B-M. Lipoproteins and BMI: a comparison between women during transition to menopause and regularly menstruating healthy women. Maturitas. 2002;41:177–185

PII: S1521-690X(02)00081-7

doi: 10.1016/S1521-690X(02)00081-7

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 33-52 , March 2003

Article Tools

* Image Usage & Resolution